value innovationcontent company consolidated financial statements shareholders perspective key aspects overview selected consolidated companies corporate bodies consolidated balance sheet consolidated profit loss statement consolidated cash flow statement group management report statement changes group equity information group notes consolidated financial statements report economic position independent auditors report report opportunities risks report expected developments financial highlights top products human pharma net sales amounts million eur unless otherwise indicated change jardiance net sales ofev family region million eur americas million eur europe asiaaustraliaafrica aaa business trajenta spiriva human pharma jentadueto animal health million eur million eur biopharmaceutical contract manufacturing sales research development expenses top products personnel expenses animal health net sales average number employees operating income operating income nexgard frontline net sales group profit million eur million eur group proft net sales group equity investments tangible assets ingelvac depreciation tangible assets heartgard circoflex flexcombo million eur million eur company making new better medicines humans animals heart mission create breakthrough therapies change lives independent familyowned boehringer ingelheim freedom pursue longterm vision looking ahead identify health challenges future targeting areas need good worldleading researchdriven biopharmaceutical company employees create value innovation human pharma animal health businesses boehringer ingelheim realized net sales billion eur investments billion eur rd drives innovation enabling next generation medicines save lives improve quality life realize scientific opportunities embracing power partnership diversity experts across lifescience community working together accelerate delivery next medical breakthrough transform lives patients generations come boehringer ingelheim annual report shareholders perspective company shareholders perspective year brought positivity two pandemic covid years people looking forward meeting reconnecting company culture thrives inperson interactions unfortunately year also brought war europe causing rising energy prices sharp increases cost living geopolitical tensions escalate despite uncertainties past year boehringer ingelheim able touch lives ever growing portfolio potential new medicine approvals coming years company exciting opportunity make profound lasting impact lives many people animals purpose transform lives generations employees made extraordinary effort demonstrate ambition innovation powerhouse gives us every confidence able address unmet patient needs years come entered optimism knowing everyone boehringer ingelheim continue drive positive change healthcare commitment key success behalf shareholders committee would like thank employees determination dedication signed christian boehringer chairman shareholders committeethe board managing directors hubertus von baumbach jean scheftsik de szolnok carinne brouillonmichel pairet michael schmelmer boehringer ingelheim annual report key aspects innovation drives us boehringer ingelheim impact lives new therapeutic solutions able help people ever despite economic geopolitical headwinds pharmaceutical industry made significant progress helping world bring covid pandemic halt raised awareness importance vaccines pandemic preparedness urgency fight antimicrobial resistance boehringer ingelheim important year determined let market uncertainties slow progress growing pipeline alone reached one fda breakthrough designation three fast track designations two orphan drug designations launched spevigo monoclonal antibody treatment patients generalized pustular psoriasis also received approval treating symptomatic chronic heart failure patients jardiance addition provided evidence patients living chronic kidney disease significantly benefit jardiance delivered promising research results key medical areas including oncology central nervous system retinal health metabolism currently pursuing clinical proof new medical products next seven years expect new medicine approvals help us address unmet needs many patients also launch range new products animals onwards businesses performed well delivering medicines helping million patients human pharma saw ongoing strong demand innovative medications led jardiance product portfolio respiratory medicine ofev animal health business felt impact economic slowdown europe north america time laying groundwork range new product launches company key aspects key overall strong performance commitment employees early research product supply engagement stakeholders heart everything equally grateful many successful scientific commercial partnerships truly appreciate value support excitement growing pipeline success current portfolio patients animals alike makes us confident future energized transform lives generations reach ever people benefit products signed signed signed hubertus von baumbach carinne brouillon dr michel pairet signed signed jean scheftsik de szolnok michael schmelmer boehringer ingelheim annual report corporate bodies shareholders committee christian boehringer chairman shareholders committee christoph boehringer erich von baumbach isabel boehringer dr mathias boehringer prof dr dr andreas barner company corporate bodies board managing directors advisory board hubertus von baumbach dr nikolaus von bomhard chairman board managing directors chairman advisory board chairman supervisory board carinne knochebrouillon mnchener rckversicherungsgesellschaft ag member board managing directors human pharma dr hagen duenbostel former chief executive officer ceo dr michel pairet kws se member board managing directors innovation dr frank mastiaux former chief executive officer jean scheftsik de szolnok enbw energie badenwrttemberg ag member board managing directors chairman advisory board sunfire gmbh animal health jan rinnert michael schmelmer ceo chairman board managing directors member board managing directors heraeus group finance group functions angela titzrath chairwoman hamburger hafen und logistik ags executive boardgroup management report information group groups business model research development production employee reporting sustainable development generations report economic position macroeconomic environment earnings position development businesses financial position net assets position report opportunities risks opportunities risk management individual risks overall statement risk situation report expected developments boehringer ingelheim annual report group management report information group groups business model boehringer ingelheim develops breakthrough therapies transform lives today gen erations come independent family owned pursue longterm vision identify challenges develop solutions areas medical therapeutic needs patients still unfulfilled insufficiently addressed aim transform lives patients across generations goal inspires employees make real significant contribution life humans animals alike boehringer ingelheim stood innovation years one strategic pillars make longterm competitive investments innovation patient wellbeing maxim makes us one researchintensive companies germany across sectors human pharma business mainstay activities accounts overall sales business area underpinned innovative portfolio many cases prod ucts standard treatments medicine research focuses cardiovascular metabol ic diseases oncology respiratory diseases immunology diseases central nervous system cns retinal health jardiance jardiance medicine treatment type diabetes also reduces risk cardio two new indications vascular diseases type diabetics preexisting cardiovascular conditions heart failure groups bestselling human pharma product net sales business human pharma million eur animal health group million eur biopharmaceutical million eur contract manufacturing million eur sales million eur group management report information group net sales region million eur americas europe asiaaustraliaafrica aaa beginning jardiance approved us fda european ema regulatory authorities treatment heart failure preserved ejection fraction addition effectiveness jardiance chronic renal failure proven empakidney study ofev used treatment rare respiratory disease idiopathic pulmonary fibrosis ipf increasingly also indication systemic sclerosis interstitial lung disease sscild recorded strong growth three products also played significant role boehringer ingelheims success spiriva used treatment chronic obstructive pulmonary disease copd well asthma trajenta used treatment type diabetes pradaxa used prevent strokes patients atrial fibrillation prevention treatment thrombo embolic disorders another milestone reached september approval spevigo substance spesolimab japan usa spevigo first product ceive fda approval treatment generalized pustular psoriasis gpp rare lifethreat ening neutrophilic disease animal health business boehringer ingelheim leading provider vaccines thera peutics portfolio includes products pets horses well livestock swine rumi nants poultry core brands nexgard followed frontline heartgard foundation success pets segment product portfolio horses expanded approval renutend europe renutend first ap proved product enhance healing tendon suspensory ligament injuries horses complementing another equine stem cell product boehringer ingelheim articell forte used treat mild moderate recurrent lameness associated nonsep tic joint inflammation horses swine segment established swine vaccine ingelvac circoflex used treat porcine circovirus type important component companys product portfolio boehringer ingelheim annual report biopharmaceutical activities comprise manufacture human pharmaceutical products actilyse metalyse praxbind spevigo also one worlds leading providers process development commercial production biopharma ceuticals thirdparty industrial customers sales mainly comprise discontinued operations financial year achieved majority sales regions americas europe asiaaustraliaafrica aaa region includes countries china strategic significance groups future development making sales research development goal research develop innovative medicines therapies treatment diseases still satisfactory treatments available aim make relevant contribution areas need treatment high well human pharmaceu ticals segment field animal health employed average people global crossdivisional research network billion eur present nine countries central facilities germany biberach ingel invested rd heim rhein usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon well china shanghai ac tivities locations continuing expand renew existing product portfolio order safeguard groups organic longterm growth accordingly increased research development rd expenses recent years past four years growth even outpaced revenue trend total approximately billion eur invested rd new medicines level previous year corresponds groups net sales rd expenses human pharma amounted billion eur research development expenses million eur net sales human pharma expenses million eur human pharma net sales animal health expenses million eur animal health net sales average number employees investments tangible assets million eur without investments infrastructure group management report information group longterm collaborations academic institutions public research institutions biotech companies pharmaceutical companies integral part rd work scientific field collaborating joint projects academic institutions spanning four continents continuously expanding accelerating rd portfolio cooperation license agreements well acquisitions longterm objective least pipeline based external innovation way combining strengths research partners strengths acknowledged high scientific standards business development relationships forged years early investments made boehringer ingelheim venture fund contribute significantly objective boehringer ingelheim also confirmed attractiveness partner new part nerships able strengthen pipeline basis example working lifebit biotech ltd biomedical data analytics provider build scalable data analytics infrastructure platform aim collaboration collect findings large exter nal biobanks thereby accelerating development new drugs together evotec se biomrieux also launched company aurobac therapeutics sas aims develop novel antibiotic precision therapies combat antimicrobial resistance amr new grant program partnership university tbingen germany aims explore new ap proaches improving human animal health ai data science methods successful start initial joint development also started another collabora tion company click therapeutics inc develop another digital health application digitale gesundheitsanwendungen diga prescribing patients schizophrenia could used alone combination drug therapy also established longterm partnerships animal health business example collaborating biopharmaceutical company mabgenesis inc accelerate discovery development new monoclonal antibodies potential canine therapies research cooperation development smallmolecule therapies canine oncology initiated carthronix collaboration focus identifying new molecules fight cancer dogs one form basic research started threeyear cooperation agreement goog le field quantum computing part digital transformation strategy partner ship aims harness computing power new technology make usable boehringer ingelheims rd thus pursue innovation rapid precise manner conserving resources time digital lab bi x expanded capabilities development approval software medical devices established center excellence throughout compa ny bi x also systematically expanding external innovation network developing digital health products global market good example consanas cloud telligent digital platform stroke patients recently launched chinese market provides access stateoftheart rehabilitation measures consanas cloud supports pa tients relatives often difficult journey back everyday life digital diagno sis treatment methods solution therefore represents milestone development digital health products china boehringer ingelheim annual report rd sites ah animal health hp human pharma bix bi x digital lab americas europe asia usa belgium china ames iowa ah evergem ah beijing ah athens georgia ah shanghai ah bi x germany colbert georgia ah taizhou ah biberach hp duluth georgia ah ingelheim rhein ah hp bi x japan fulton missouri ah kathrinenhofrohrdorf ah kobe hp north brunswick new jersey ah ochsenhausen hp ridgefield connecticut hp st joseph missouri ah france lyon boreal ah lyon porte des alpes ah saintvulbas ah netherlands lelystad ah austria innsbruck hp vienna hp switzerland basel hp geneva hp group management report information group since boehringer ingelheim venture fund driven innovation investments young companies carrying research earlystage science technology venture fund invests biotech startup companies innovative concepts technologies potential provide groundbreaking new therapeutic platforms venture fund also creates companies identifies research projects universities academic insti tutions established venture fund asia alongside existing venture funds germany usa research institute molecular pathology imp vienna biomedical research institute group company boehringer ingelheim scientists approxi mately countries imp conducts research molecular cellular mechanisms form basis complex biological life processes well human diseases imp one leading institutions kind late ten group leaders received least one prestigious grants awarded european research council erc seven group leaders elected full members european molecular biology organization embo open innovation platform opnmecom boehringer ingelheim contributing pro cess scientific collaboration pharmaceutical world molecules preclinical stage currently made available academic researchers around world free charge form collaboration already enabled new scientific findings field oncology example boehringer ingelheims rd activities preclinical well clinical rd basis sustainable success groups positive business development past years underpinned organic process renewing portfolio based rd activ ities inhouse rd supplemented external cooperation partnerships also con tinue top priority future high level innovation reflected pipeline three fda breakthrough therapy designations btd another btd bi novel experimental phosphodiesterase b pdeb inhibitor confirmed financial year decline lung function patients idiopathic pulmonary fibro sis ipf reduced help bi human pharma human pharma business rd contributed purpose transform lives new generations achieved important milestones pipeline launches new indi active substances cations within different disease areas cardiometabolic diseases oncology respiratory human pharma diseases immunology diseases central nervous system cns portfolio human pharma portfolio included overall around clinical preclinical projects based new molecules boehringer ingelheim annual report development pipeline end cardiometabolic diseases phase glpfgf agonist phase heart disease modulator phase bi trpc inhibitor fsgs phase ii bi glpgcgr agonist nash phase ii bi glpgcgr agonist obesity phase ii bi sgc activator csph phase ii empagliflozin bi sglt inhibitor aldosterone synthase inhibtor ckd phase ii empagliflozin new indication sglt inhibitor post mi phase iii empagliflozin new indication sglt inhibitor ckd registration oncology phase bhcd tcell engager phase dllcd tcell engager phase cdfap agonist phase ezabenlimab pd antibody phase tki phase kisima cancer vaccine phase kras gc inhibitor phase mdmpantagonist phase vsvgp phase heterologous prime boost vaccine phase sirpantagonist phase pan kras sos inhibitor phase trailrcdhantibody phase bi mdmpantagonist ddlps phase ii respiratory diseases phase ion channel inhibitor phase lysophospholipase inhibitor phase bi catc inhibitor ncfb phase ii bi pdeb inhibitor ppf phase ii bi pdeb inhibitor ipf phase iii group management report information group development pipeline end continued immunology phase pd antibody phase bi kinase inhibitor cd phase ii spesolimab ilr antibody hs phase ii spesolimab ilr antibody gpp flare prevention phase ii spesolimab ilr antibody gpp flare treatment registration central nervous system diseases phase phosphodiesterase inhibitor phase digital therapeutic phase nmda regulator phase bi mdd phase ii bi bpd phase ii bi ptsd phase ii iclepertin glyt inhibitor cias phase iii retinal diseases phase phospholipid modulator phase vascular modulator phase bi ischemia modulator dmi phase ii bi semaa antibody dmi phase ii investigated combination therapies key pipeline advances breakthrough therapy designation granted us food drug administration partnered projects acquired assets prevention hf post mi approved us europe china japan treatment generalized pustular psoriasis gpp flares adults indication abbreviations bpd borderline personality disorder ddlps dedifferentiated liposarcoma ipf idiopathic pulmonary fibrosis cd crohns disease dmi diabetic macular ischemia mdd major depressive disorder cias c ognitive impairment associated fsgs f ocal segmental glomerulo mi myocardial infarction schizophrenia sclerosis nash n onalcoholic steatohepatitis ckd chronic kidney disease gpp generalized pustular psoriasis ncfb noncystic fibrosis bronchiectasis copd c hronic obstructive pulmonary hf heart failure ppf progressive pulmonary fibrosis disease hs hidradentis suppurtiva ptsd posttraumatic stress disorder csph clinically significant portal hypertension boehringer ingelheim annual report cardiometabolic diseases year began indication extension empagliflozin adults suffering heart failure preserved ejection fraction ema us fda approvals based first clinically proven benefit patients symptomatic chronic heart failure including preserved ejection fraction addition phase iii empakidney study stopped early due positive efficacy empagliflozin adults chronic kidney disease results study present ed asn congress showed superior benefits empagliflozin patients chronic kidney disease ckd versus placebo submission marketing authorization new em pagliflozin indication ckd regulators took place core markets planned world wide moreover results dinamo trial presented idf congress showed empagliflozin first sglt inhibitor show statistically significant reduction blood sugar levels children adolescents type diabetes completed phase trial glucagon receptor glp receptor dual agonist bi people obesity bi also investigated another phase trial people nash liver fibrosis ff aldosterone synthase inhibitor bi investigated phase trial alone combination empagliflozin people chron ic kidney disease without type diabetes bi received fast track designa tion us fda october oncology oncology aspiration improve lives people cancer delivering meaningful advances ultimate goal significantly sustainably improve life expectancy num ber types cancer long term robust pipeline homegrown licensed partnered clinical assets diverse range mode actions including cancer celldirected immunooncology investigational therapies smart combination approaches may offer greatest benefit people living cancer started two pivotal phase lllll trials mdmp antagonist bi socalled brightline trial investigates bi compared doxorubicin firstline treatment people advanced dedifferentiated liposarcoma rare aggressive form liposarcoma us fda granted orphan drug designation bi treatment soft tissue sarcoma brightline investigating drug secondline treatment beyond people specific form biliary tract carcinomas pancreatic cancer respiratory diseases another focus boehringer ingelheim rd new therapeutic options people respiratory diseases high unmet need since ofev nintedanib treatment option idiopathic pulmonary fibrosis ipf slow decline lung function ofev approved treatment ipf countries sscild systemic sclero sisassociated interstitial lung disease countries pfild progressive fibrosing interstitial lung disease countries published results inpedild trial group management report information group investigating dosing safety profile nintedanib children adolescents based findings regulatory applications submitted european medicines agency followed submission us fda accepted nintedanib would become first approved treatment pediatric patients fibrosing interstitial lung disease addressing high unmet need underserved patient population despite advances therapy new treatments urgently needed complement existing therapies help stop rather slow disease progression company reported promising week phase ii trial data bi novel investigational phosphodiesterase b pdeb inhibitor showed reduction rate lung function decline patients idiopathic pulmonary fibrosis ipf potential new treatment builds leadership lung fibrosis bi investigated two phase iii pivotal clinical trials initiated fibroneeripf patients idiopathic pulmonary fibrosis fibroneerild people living progressive fibrosing inter stitial lung diseases immunology immunological diseases greatly impact patients lives physically psychologically boehringer ingelheim dedicated discovering developing firstoftheirkind therapies serious inflammatory diseases deep understanding molecular pathways pioneering scientific breakthroughs target repair prevent inflammatory diseases skin gut joints spesolimab marketed spevigo advanced immunological compound current boehringer ingelheim pipeline received approvals major markets treatment gpp flares adults received marketing authorization us fda ema china japanese authorities approvals based positive phase ii data effisayil trial central nervous system diseases boehringer ingelheim evolving mental health research enable people thrive people mental health conditions carers benefit treatment experience provides predictable outcomes within approach link behavior underlying neurobiology develop targeted therapies innovative approaches digital therapeutics strive enable people mental health conditions create mean ingful connections lives loved ones society one example approach bi currently investigate clinical phase ii trials people living borderline personality disorder posttraumatic stress disor der major depressive disorder bi received fasttrackdesignation us fda posttraumatic stress disorder addition borderline personality disorder completed phase trial compound indication january boehringer ingelheim annual report animal health line abovementioned goal operating areas high medical need also con centrate animal health discovery development highly innovative treatments preventive therapies among things includes therapeutics oncology im munology new chemical entities new methods control counter resistance parasites well new tools technologies improve prevention infectious diseases current portfolio includes innovative vaccines parasiticides protection pets livestock well pharmaceutical products treatment chronic diseases research increasingly incorporates new approaches technologies use stem cells monoclonal antibodies innovation strategy built scientific approach investigation causes mechanisms diseases across multiple animal species leading discovery new ways mitigate causes intervene disease process three focus areas rd infectious disease noninfectious disease parasiticides work also use experience human pharma research well external partners areas outside animal health rd sites organized six regional innovation centers located usa europe china ensures concentration critical mass expertise needed deliver therapies customers key geographies designated sites within region serve focus specific segments overall strategy footprint strengthens local execution facilitates regional external networks partnerships synergies key advantage boehringer ingelheim retain human pharma animal collaboration health divisions teams human pharma animal health work together share knowl human pharma edge specific disease mechanisms chemistry compounds cutting edge techniques animal health previous years successfully introduced products aservo equihaler semintra resulted synergies human pharma animal health teams additional promising compounds pipeline expect innova tion connection particularly area therapeutics external collaborations also play key role initiated new strategic partnerships including partnership carthronix biopharmaceutical company focused developing small moleculebased therapies degenerative agingrelated diseases collaboration focus identifying new molecules target cancers dogs boehringer ingelheim test select group small molecules provided carthronix goal determining impact canine cancers also entered partnership mabgenesis inc private bio pharmaceutical company headquartered yokohama japan collaboration aims discover innovative canine therapeutic antibodies using mabgenesis incs platform technologies furthermore continue work key research institutions around globe develop new solutions unmet medical needs example efforts develop effective approaches prevent african swine fever continues cause massive losses pig populations led partnerships friedrichloefflerinstitut pirbright institute oxford university among others initiated research development clinical studies worldwide awarded product registrations key new approvals include renutendtm europe new stem cell therapy improve healing tendon suspen sory ligament injuries horses vetmedinca usa received conditional approval new fda procedure first drug delay onset canine congestive heart failure dogs preclinical myxomatous mitral valve disease europe countries group management report information group middle east received approval fencovis new vaccine prevent calf diarrhea fencovis provides passive immunity calves maternal colostrum obtaining approvals new products new areas application well expanding geographic scope sales activities existing products additional important aspects rd activities production human pharma human pharma business globally active production facilities responsible steady supply topquality medicines patients ongoing development companys internal production facilities strategic cooperation external manufacturers established modern flexible market supply network encompasses entire value chain suppliers starting materials worldwide logistics distribution finished phar maceutical products boehringer ingelheims production facilities focus products strategically important company well stateoftheart manufacturing technolo gies time partnerships external manufacturers add specialist technologies production network available inhouse also expand production capac ity standard technologies products high capacity requirements reached advanced point life cycle financial year global network included boehringer ingelheims plants nine countries group four biopharmaceuticals facilities also two facilities manufacture pharmaceutically active substances one produces medical devices finished pharmaceutical products manufactured packaged eight facilities past year presented particular logistical challenges due ongoing effects covid pandemic effects russiaukraine war boehringer ingelheim able ensure steady supply medicines patients alongside use appropriate safe ty stocks possible thanks establishment key manufacturing steps tech nologies multiple facilities different geographical regions cases strengthening resilience concept every link supply chain significant contribution development supply security progress digital trans formation production network entire supply chain control value chain supplier customer endtoend optimized great er implementation supply chain strategy use digital automated processes technologies enables high level transparency efficient control global production networks supply chain boehringer ingelheim annual report production facilities ah animal health hp human pharma bio b iopharmaceutical contract manufacturing americas europe asia brazil belgium greece china itapecerica hp evergem ah koropi hp nanchang ah paulnia ah shanghai hp bio denmark great britain taizhou ah mexico kalundborg ah pirbright ah guadalajara ah indonesia germany italy xochimilco ah hp bogor hp biberach bio fornovo hp puerto rico dortmund hp noventa ah japan barceloneta ah ingelheim rhein hp yamagata hp austria usa france vienna bio athens georgia ah grand lyon industrial spain fremont california bio biologic center ah sant cugat hp gainesville georgia ah toulouse ah st joseph missouri ah composed three sites lyon portedesalpes lentilly jonage group management report information group delivery capability patient care top priorities boehringer ingelheim company consistently makes important investments development transformation produc tion capacities chemical pharmaceutical network ingelheim rhein head quarters key investment flexible plant industrialization newly developed inno vative medicines initial market supply fully executed expansion production technologies capacities active pharmaceutical substances ingelheim rhein germany fornovo italy sites pharmaceutical bulk goods finished medicinal products sant cugat spain koropi greece sites initiated pushed forward sustained manner ensure supply antidiabetics particular jardiance well pipeline products operational activation biopharmaceuticals largescale cell culture production building vienna facility represented milestone expansion capacities network newly developed products well strengthening bio pharmaceutical business global quality vision quality safety successfully implemented help global quality transformation program transformation de signed last years quality processes systems strengthened prepared future requirements quality manifested competitive advantage important contribu tion cultural transformation rollout highly developed quality culture patient focus actions every employee actively contributes animal health animal health products manufactured network production facilities nine countries addition companys facilities around contract manu facturers manufactured medicines boehringer ingelheim product portfolio essentially animal health consists vaccines pharmaceutical products nutraceuticals successfully expanded production facilities launch innovative packaging technology twistpak chemical medicines nine countries vaccines supplemented stem cell therapeutics diagnostic products well monitoring solutions include digital applications used livestock monitoring link livestock owners veterinarians boehringer ingelheims investments inter alia expand capacities topselling product group nexgard barceloneta puerto rico site manufacturing capacities jonagelyon france continued include construction modern plant vaccines highest biological safety standards production network optimization already begun advanced objective reliable efficient delivery products biopharmaceutical contract manufacturing boehringer ingelheim performs biopharmaceutical activities facilities biberach one leading germany vienna austria fremont california usa shanghai china comprise biopharma provid manufacture ownbrand marketable products actilyse metalyse ers industrial praxbind spevigo biopharmaceuticals clinical testing boehringer ingel customers heim also one worlds leading companies process development launch preparation commercial production biopharmaceuticals thirdparty industrial customers twelve top pharmaceutical companies innovative biotech firms clients bio pharmaceutical contract manufacturing business boehringer ingelheim covers entire bio pharmaceutical value chain regard development production cell mammalian cells well microorganisms production process manufacture active substance finished pharmaceutical product product launch global market supply boehringer ingelheim annual report capacity utilization networks industrialscale production facilities remained high level maximum production volume actilyse reached bibe rach site inhouse process transfer new largescale cell culture facility vienna carried established market product future product manufactured parallel two boehringer ingelheim sites way optimally use advantages global biopharmaceutical production network ensure reliable connection patients furthermore boehringer ingelheim ilr monoclonal antibody spesolimab trade name spevigo successfully launched biberach site september built balanced latestage commercial product portfolio microbial production facility vienna despite challenging external situation associated covid cell culture plants biberach shanghai fremont microbial production vienna continued manufacture deliver biopharmaceuticals reliably patients worldwide employee reporting boehringer ingelheim employed people average worldwide represents increase previous year average number employees region americas europe asiaaustraliaafrica aaa committed employees identify companys aims find work atmos phere boehringer ingelheim positive appreciative major success factor driv ing groups positive growth high level personal commitment every day help us fulfill joint promise ensuring supply vital medicines annual global employee survey provides us relevant feedback enables us continuously improve work environment boehringer ingelheims success based innovation well presence countries global nature value chain international nature clientele stringent wideranging requirements national regulators demand great flexibility organiza tion whole convinced relationships based trust well mutual openness respect empathy values make us strong competitive diversity thought spirit inclusion relationships one another promote capacity innovation every area business boehringer ingelheim convinced future holds unique opportunities innovation sustainability better health companywide purpose transforming lives generations expression ambition create better future upcoming generations unites us order optimally equip employees future require ments constantly changing health labor market made lifelong learning group management report information group development personnel priority corporate strategy addition access external offers employees worldwide linkedin learning online lan guage provider gofluent company established businessarea topicspecific academies early objective building required skills internally focused manner examples data science academy opened november univer sity medicine excellence founded july data science academy various target groups beginners data experts find tailormade learning opportunities use data analyses respective areas responsibility employees trained internally field data data science almost employees various medical disciplines took part university medicine excellences threemonth inaugural program accelerate program developed rolled renowned harvard medical school another important cornerstone developing specialists tomorrow training pro grams different scientific technical commercial training courses cooperative study programs company offers young people opportunity get started profes sional lives average young people worldwide enrolled boehringer ingelheims vocational training program total young people started german loca tions boehringer ingelheim alone selection training cooperative study programs closely coordinated disciplines ensure curricula training programs meet needs one companys important objectives strengthen appeal boehringer boehringer ingel heim employer addition attractive career paths boehringer ingelheim offers ngelheim additional benefits workforce include range company pension plans flexible r ecognized homebased work options numerous healthrelated benefits company global top recognition top employer auditors international inde employer pendent top employers institute institute rated company particularly well globally areas business strategy values ethics integrity boehringer ingelheim placed competitors overall average especially area rewards recognition addition independent institute also highlighted areas diversity inclusion onboarding sustainable development agile working methods seen growth last three years award key countries three regions makes us global top employ er employers worldwide hold title addition germany boehringer ingelheim also awarded argentina australia austria brazil chile china colombia ecuador france great britain hungary indonesia italy malaysia mexico netherlands new zea land philippines poland romania russia saudi arabia singapore south korea spain thailand united arab emirates vietnam boehringer ingelheim annual report sustainable development generations sustainable sustainability firmly anchored corporate philosophy since boehringer ingel evelopment heims founding understanding awareness sustainability developed part strategy generations continues influence decisionmaking actions focus human animal health boehringer ingelheim well positioned address interconnected sustainable development challenges subsequently provide relevant contribution healthier sustainable future sustainability strategy entitled sustainable devel opment generations based following three pillars health good health people animals potential good health communities people green good health planet pillars boehringer ingelheim implements initiatives around globe drive companys contributions impact alignment united nations sustainable development goals base year aim achieve following concrete measurable goals health expanding access healthcare additional million people vulnera ble communities investing billion eur health innovation research tackle non communicable diseases additional million eur partnerships combat emerging infectious diseases potential aim positively impact million people vulnerable communities empowering supporting employees partners innovative social entrepreneurs green become carbonneutral company operations scope also significantly reduce resource footprint across value chain period despite growing business activities health good health people animals health health follows ambition develop better therapies enable better solutions focus global healthcare challenges pillar includes number projects initiatives reflecting health people diversity patients expertise partners include animals access healthcare access healthcare initiatives seek improve healthcare vulnerable communities disease awareness diagnosis effective prevention care availability medicines achieved several milestones including expanding access healthcare less developed regions un defeatncd part nership publicprivatepeople partnership envisions universal health coverage noncommunicable diseases ncds boehringer ingelheim joined defeatncd partner ship currently collaborating around four interconnected pillars national ncd capacity building community scaleup ncd services affordability accessibility essential ncd supplies financing countrylevel ncd programming first coun tries focus india gambia rwanda djibouti world health summit october boehringer ingelheim partners discussed progress improved care patients ncds collaboration partnership group management report information group access healthcare initiative offers comprehensive program patients screening followup program started kenya screening referral chronic obstructive pulmonary disease copd followed patients enrollment access spiriva tiered price achieve equitable access support adherence patients low income pathways indigenous health collaborations project canada aims impact lives members indigenous communities addressing high prevalence certain noncommunicable diseases ncd communities pro gram established indigenousled indigenousinformed vi sion close health gap experienced indigenous communities focusing relationship building positive sustainable future partners currently four pilot projects underway british columbia alberta manitoba nova scotia tai lored individual needs respective communities similarly various initiatives collaboration healthcare professionals patient advocacy groups national pharmaceutical management agency assist indigenous communities new zealand equitable access new type diabetes td medication collaborated experts ngos global alliance rabies control garc set pilot mass vaccination programs dogs intent design new models scale rabies elimination sustainably effort aims fighting rabies vulnerable communities endemic countries controlling rabies animals thereby helping reduce human death toll disease stop rabies piloting initiative launched south africa effort enable sustainable dog vaccination campaigns vulnerable communities boehringer ingelheim vaccinated dogs collaboration khula outreach program south africa partners local government tackle rabies angels angels initiative aims improve stroke care worldwide additional clin ics around doctors nurses paramedics joined network angels initia tive biggest stroke community world includes healthcare professionals hospitals countries helped ensure estimated million patients treated line defined standards product donations product donations aimed complementing boehringer ingelheims access healthcare efforts providing medicines vulnerable communities otherwise would access product donations reached patients countries world wide also includes product donations million eur patients ukraine lastmile lastmile initiative launched stretching across subsaharan africa reached smallholder farmers kenya cameroon nigeria mali burkina faso ethiopia enabled product registrations initiative aims train smallholder farmers vulnerable communities prevention animal diseases leveraging access healthcare solutions vaccines treatments optimize health productivity livestock boehringer ingelheim annual report potential good health communities people potential potential focused providing health well best possible conditions focus people people boehringer ingelheim communities partners reach full communities potential safe safe program established place particular emphasis importance ensuring safe workplace employees partners continu ously review optimize work safety culture global network safety ex perts striving maintain employees good health preventing incidents accidents occupational health risks communicated regularly internally management col leagues partners communities global level ambition successfully transform organization one driven enforcement rules creating corporate culture safety embedded creating value people bring safety culture mindset high five safety initiative created addresses frequent safety concerns well offering support employees stay safe lead example encourage others daily work life furthermore boehringer ingelheim became official partner euo sha healthy work places lighten load campaign prevent work related musculoskeletal disorders msds continued healthy healthy program established better support employees additional knowledge tools resources maintain necessary improve health wellbeing workplace program defined set global health wellbeing stan dards implemented international network health wellbeing ambassadors health navigators foster healthy company culture promote stronger awareness physical mental health healthy habits diversity equity inclusion dei core values empathy respect passion trust foster diverse collabora tive open inclusive work environment key innovation value creation sustainable growth boehringer ingelheim convinced valuing diversity fostering inclusive environment right thing people communities also smart thing business since helps us better understand fulfill different needs patients customers partners around globe organizationally enable aim open collaborative inclusive culture corporate dei office dei champions around globe representing different countries regions global culture dei council boehringer ingelheim also promotes social wellbeing encouraging employee resource groups ergs networking company ergs networks voluntarily formed leadership sponsored erg women tech founded members aim connect empower women work ing technology boehringer ingelheim group management report information group furthermore company enables employees raise voice case potential noncompliance speak procedure pursues mediation biases inequities within systems processes practices boehringer ingelheim continues train leaders employees unconscious bias inclusive behaviors etrainings completed since december masterclass program integration dei employee onboarding leadership development programs etrainings held first time languages addition german english human rights boehringer ingelheim continuously stepping efforts areas human rights ethics approach aligned united nations guiding principles business human rights human rights embedded company culture underlined human rights environmental health safety sustainability policies human rights integrated business code conduct supplier code conduct environmental health safety ehs compliance program continuing focused implementation components required forthcoming german supply chain due diligence law goes effect january making health boehringer ingelheim ashoka worlds largest network social entrepreneurs jointly established making health mmh initiative longterm partnership focuses enabling innovative solutions tackle complex healthcare challenges people animals communities approach links interdependent issues economic development infrastructure education culture healthcare issues emphasizes collabo ration communities equal partners engages boehringer ingelheim employees share knowledge skills mmhs individual initiatives form holistic continuum generates impact various levels supporting vulnerable communities financing social enterprises highlights include social innovation date social entrepreneurs worldwide working areas human animal health supported community activation since programs established india sub saharan africa proven groundbreaking already reached people reached alone includes clean water hygiene projects implementing innovative farming models providing animal health business skills training courses well inclusion programs marginalized community groups people albinism support social businesses supported social enterprises making health business accelerator program five joined program cooperation partner villgro afrika five social enterprises focus animal health accepted part new incubation program rising stars programs assist social startups subsaharan africa financial means management skills employee engagement accelerate scaleup sustain business model boehringer ingelheim annual report making health together convention twoday hybrid event ingelheim germany nairobi kenya brought together participants industry govern ment civil society academia social entrepreneurship impact financing connect collab orate innovate towards achieving sustainable solutions pressing healthcare issues making health together focuses social entrepreneurship innovative approaches solving healthrelated challenges boehringer ingelheim social engagement impact engagement fund leverages innovative financing tools beyond grant funding donations intention continue support amplify social impact sustaining scalingup social businesses subsaharan africa aim create portfolio comple mentary social businesses address healthcare challenges cowtribe inc leading lastmile veterinary delivery company ghana announced first investment recip ient cowtribe supports farmers remote regions ghana ensuring supply essential vaccines animals investment intended reach significantly farmers animals already supported green health planet green healthy planet prerequisite healthy people animals communities environmental focus challenges seen isolation interconnected tangible e nvironment effects health entire societies subsequently sustainable use natural resources applying ecodesign green chemistry concepts promotion strong environ mental awareness key components environmental sustainability program order help protect health current future generations safeguard prospects healthy future green fund supports internal projects areas circular economy decarbon ization water management already provided funding new environmental projects worldwide since boehringer ingelheim pays particular attention environmental sustainability aspects major projects set aside additional million eur purpose boehringer ingelheim first pharmaceutical company eu receive greencanteen certification sustainable catering concept ingelheim head quarters building dortmund site certified currently total five corporate canteens received certification germany two belong boehringer ingelheim carbon footprint continuously working reducing greenhouse gas emissions committed becoming carbon neutral company operations scope using newable electricity continuing make substantial investments sustainable technology one tools used process introduction internal carbon price eur per ton create additional economic incentive green innovation examples activ ities reduce greenhouse gas emissions include group management report information group new certification carbon neutrality sites kathrinenhofrohrdorf germany gainesville georgia usa shanghai china total five sites addition dort mund germany sant cugat spain transition renewable electricity solutions numerous locations including sites austria germany spain usa since year companys share renewa ble electricity purchased worldwide increased construction new solar plant headquarters ingelheim nearing completion initiation supplier collaboration program key suppliers intention reduce co emissions value chain scope performance measured via digital platform continued partnership climateseed support reforestation projects africa canada china india indonesia germany offseting unavoid able carbon emissions also strengthening biodiversity protecting drinking water resource use circular economy aspects implemented stages value chain minimize waste apply eco design green chemistry concepts new products continuous opti mization measures reduced annual volume waste landfills resource use increasing recycling reuse rates since thus optimizing environmental footprint future boehringer ingelheim products specifically integrating criteria sustainability design products rd phase product lifecycle innovation unit iu working towards reduc ing environmental footprint medicines approach utilizes principles ecodesign green chemistry across global rd organization starting synthesis drug substances packaged products achieved several milestones including establishing iu green grant program aiming accelerating sustainable science technology innovation academic collaboration creating new options ecodesign already launched first research challenge open innovation platform openme launch iu green award recognize outstanding implementation green chemistry green engineering ecodesign concepts well demonstrating compelling environmental health safety efficiency improvements first winning team awarded iucon conception ecodesign playbook better evaluate implement ecodesign green chemistry criteria pharmaceutical development water stewardship access clean water major impact social cultural justice environmental sustain ability local economy reason boehringer ingelheim implements programs lated water related risks production sites sites established water scarcity areas implement water stewardship program alliance water stewardship aws production site fremont california usa received aws certification second site following aws certification promeco production facility xochimilco mexico boehringer ingelheim annual report furthermore evaluated wastewater production sites regarding possible resi dues active pharmaceutical ingredients api trace substances basis clean water initiative ensures traces pharmaceuticals wastewater remain signifi cantly effect level initiative also collaborates industrial networks sup pliers encompass entire value chain context boehringer ingelheim also enables joint projects initiative making health kenya aim improve access clean water example construc tion solarpowered water tower storing water nearby kibisi dam water dis penser stations providing water distribution public facilities private homes pro ject estimated positively impact lives people local community group management report report economic position report economic position macroeconomic environment global economy faced immense economic challenges according international monetary fund imf global economic growth fell russias war aggression ukraine associated sanctions imposed russian prod ucts led sharp increase gas energy prices beginning continued course year due significant restrictions placed russian natural gas supplies time electricitygeneration costs gasfired power plants rose also led significant price increases electricity market high energy prices resulted higher production costs companies led reduced purchasing power private house holds companies forced reduce energy intensity shortage goods rising energy prices significant drivers global increase inflation nevertheless global pharmaceutical market excluding covid vaccines grew growing human eur trillion last year corresponded compound annual growth last pharma market five years source iqvia particularly case pharmaceutical market con allowed increased trast sectors tends characterized long term performance na investment rd tional economies particular demographics respective societies addition average growth market influenced constant improvement global access medical care russias war aggression ukraine indirectly led higher energy production costs pharmaceutical companies also boehringer ingelheim however sales prices often regulated change high rates inflation led interest rate hikes numerous countries central banks increase financing costs greater volatility currency market time government regulatory programs combat inflation adopted several countries direct impact pharmaceutical industry impact future financial years inflation reduction act ira us particularly noteworthy regard effects covid pandemic continued negative impact negative eco nomic impact covid pandemic means fully overcome internation al supply chain disruptions continued affect industrial production china also restrictions due temporary lockdowns negative impact demand medi cines time costs combating covid pandemic led high additional burdens healthcare systems many countries order address challenges many healthcare systems expanding use costcontainment tools mandatory price reductions pharmaceutical products external price reference systems lengthy well complex negotiation processes delay access innovative new medicines patient also increasingly involved covering cost treatments using different copayment models germany savings plans politicians healthcare system implemented via gkv statutory health insurance financial stabilization act gkvfinanz stabilisierungsgesetz specifications could increase cost pressure pharmaceu tical companies reduce willingness invest germany uk pharmaceutical companies participating vpas voluntary scheme branded medicines pricing boehringer ingelheim annual report access pay higher reimbursements health authority due increased health care spending repayment rate increased rate set measures increasingly putting pressure pharmaceutical companies therefore may limit future ability invest development new treatment options pro vide innovative medicines pharmaceutical industry works closely governments public health authorities meet challenges order ensure improve access medicines sustainable manner reduce delays market approval provide patients innovative medicines important prerequisite achieving objective remains reliable legal framework promotes innovation ensures protection intellectual property tendencies eu level aimed weakening incentive instruments would send wrong signal cuttingedge research investment pharmaceutical innovation competitiveness would decline could make difficult european patients participate clinical trials access new innovative therapies animal health animal health market consisting pet livestock segments continued growth market continues trend compared previous years growth slowed reporting period par positive growth ticular due consumer behavior adjustments response high inflation supply chain trend issues longterm drivers growth population growth rising standard living many people growth markets increased life expectancy animals due constant improvements veterinary care pets increasingly seen life companions whose health important owners reflected increased demand products pet segment livestock segment benefited increased demand animal protein continuous growth consumer awareness regard highquality products increasing prevalence zoonotic diseases infectious diseases transmissible animals hu mans humans animals reinforcing importance animal health industry general consolidation mergers customer side ongoing leads creased competition future growth animal health business largely driven therapeutic innovation order grow market investments need continuous sustainable competitive according imf global economic growth amount forecast imf represents significant slowdown global economic growth according oecd imf inflation remain high expected decline many countries global inflation therefore projected ease according imf numerous additional risks could significant impact economic growth mis calculation monetary policy lower inflation higher energy food prices could lead inflation lasting longer furthermore tighter financing conditions could significant impact companies also emerging market debt economic growth could hampered new global health fears renewed effects covid addition ongoing crisis chinas real estate sector could affect domestic banking sector growth china could involve crossborder implications furthermore global supply chains could per manently impaired due geopolitical fragmentation consequently make cooperation climate policy difficult addition ongoing climate change increasing risk occurrence natural disasters therefore related health economic impacts group management report report economic position currency development boehringer ingelheims global presence means currency trends influence financial per formance us dollar usd japanese yen jpy chinese renminbi cny particularly worthy note extraordinarily high inflation prompted us federal reserve particular significantly raise key interest rates supported appreciation usd currencies low eurusd february beginning year us dollar fluctuated end year low high eur usd october japanese yen fluctuated high eurjpy january low eurjpy november chinese renminbi started year eurcny january high achieved midyear eurcny july low reached towards end year eurcny december significant transactional currency risks hedged suitable currency instruments currency development effect net sales average rate basis eur million eur us dollar japanese yen chinese renminbi earnings position boehringer ingelheim stable competitive financial performance solid financing basis independence making focus actions basis imple ment corporate purpose transforming lives generations invest innovation competitive scale thereby making contribution improving human animal health innovative therapies boehringer ingelheim continued positive growth trend generated net sales million eur corresponds increase compared previous years revenue million eur exchange rate effects positive impact reve billion eur nue development adjusted effects group growth net sales net sales region million eur currency change adjusted americas europe asiaaustraliaafrica aaa boehringer ingelheim annual report achieved net sales growth every region previous years net sales mil lion eur share overall sales americas region boehringer ingelheims key sales market growing currencyadjusted furthermore net sales growth region europe improved past financial year currencyadjusted sales also include global license business amounted million eur corresponded share group sales positive trend driven global li censing business allocated region well markets germany spain countries eastern europe asiaaustraliaafrica aaa region net sales increased currencyadjusted million eur key figures million eur change net sales operating income return net sales income taxes income taxes due significant increase net sales products jardiance family ofev materials ratio taking account change inventories fell personnel expenses rose aboveaverage rate alongside addi tional employees areas research development medicine strategically important boehringer ingelheim production biopharmaceutical medicines also due adjustments pensions inflation expectations pension trends well currency effects amortization intangible assets depreciation tangible assets million eur higher compared previous year particularly attributable impairment losses intangible assets impairment losses acquired rd projects due risk inherent researchbased pharmaceutical industry development innovative medicines addition scheduled depreciation amortization increased due continued high investment activity currency effects financial year operating result increased slightly million eur due positive operating development compared previous year despite increased costs high impairment losses nonreoccurring charges pleasing development busi nesses net sales provides us basis sustainably invest rd able crease expenses rd percentage sales approximately financial year basis return net sales fell also due higher prices procurement markets increased number employees strategically important areas investments financial income declined primarily due developments stock markets impact budgeted assets pensions similar obligations loss allowances nonconsolidated investments also reduced holding income income taxes thus fell million eur despite slight increase operating result group management report report economic position income taxes fell million eur slightly higher tax rate must noted regard provisions german commercial law shareholders personal taxes aris ing group business activities may recognized tax expenses instead taxes presented part withdrawals group equity taking specificity ac count actual tax burden markedly higher figure shown profit loss statement consolidated profit million eur overall financial year year positive corporate development boehringer ingelheim cost increases nonreoccurring charges largely offset positive business development despite challenging market billion eur conditions group profit development businesses past year boehringer ingelheims activities divided human pharma animal health biopharmaceutical contract manufacturing businesses net sales businesses million eur currency change adjusted human pharma animal health biopharmaceutical contract manufacturing sales human pharma human pharma business made products available patients thanks new approvals additional countries also strengthened established products million patients treated products human pharma business mainstay boehringer ingelheims activities accounts share groups net sales net sales human pharma business increased currencyadjusted financial year million eur growth mainly driven established products jardiance family well ofev growing volume licensing business particular skyrizi licensed abbvie responsible marketing product also made key con tribution positive development human pharma business boehringer ingelheim annual report human pharma net sales top products million eur currency change adjusted jardiance family ofev trajenta jentadueto spiriva pradaxa jardiance product highest net sales jardiance addition treat ofev drive growth ment type diabetes also used treatment chronic heart failure jardiance family generated net sales million eur therefore currency adjusted higher previous year ofev second largest product net sales primarily used treat idiopathic pulmonary fibrosis two indications sscild pfild ofev recorded net sales million eur therefore achieved growth rate currency adjusted previous year trajenta jentadueto used treat type dia betes achieved revenue growth net sales increased currencyadjusted million eur product spiriva used treat chronic obstructive pulmonary disease copd asthma developed line product life cycle net sales million eur level previous year currencyadjusted due currency reasons net sales anticoagulant pradaxa declined line product life cycle fell currencyadjusted compared previous year however net sales million eur pradaxa continued one boehringer ingelheims five topselling medicines financial year increase net sales currencyadjusted also achieved license income skyrizi product marketed globally partner abbvie based substance risankizumab largely developed boehringer ingelheim used treat moderate severe plaque psoriasis psoriatic arthritis additionally med icine approved markets treatment moderately severely active crohns disease sales volume financial year therefore also reflects related non reoccurring milestone payments human pharma business achieved growth every region yearoveryear terms regional distribution revenue usa remained strongest revenue contributor growth rate currencyadjusted million eur represents almost share human pharma businesss overall net sales group management report report economic position achieved net sales million eur eucan region europe canada growth rate currencyadjusted eucan region therefore generated sales share compared previous year companys emerging markets also registered improved volume sales past finan cial year growth rate currencyadjusted overall net sales countries rose million eur doubledigit growth generated com pared previous year market china remained challenging due vol umebased procurement mechanisms well covid lockdowns part able record slight sales growth compared previous year currencyadjusted due favorable exchange rates japan accounted approximately total net sales human pharma business net sales fell currencyadjusted million eur due significantly weaker japanese yen compared euro human pharma net sales region million eur currency change adjusted usa eucan emerging markets japan animal health past financial year animal health business achieved revenue totaling mil lion eur therefore provided almost groups revenue animal health able increase revenue currencyadjusted supported currency effects animal health net sales top products million eur currency change adjusted nexgard frontline heartgard ingelvac circoflex flexcombo topselling animal health medicines come pet business antiparasitic nexgard recorded sales growth currencyadjusted million eur therefore remained highestselling product family portfolio animal health division financial year growth products nexgard spectra nexgard combo nexgard family became one topselling brands animal health industry able reach milestone one billion eur sales boehringer ingelheim annual report contrast antiparasitic frontline medicine heartgard recorded decline net sales due increased competition high inflation forced many pet owners prioritize household budgets particularly usa significant influence declining sales observed ingelvac circoflex swine vaccine net sales fell currencyadjusted million eur mainly due difficult market environment china animal health able exceed previous years net sales almost regions essentially attributed currency effects usa grew currency adjusted able compensate decline sales swine egment particularly pet segment including horses slight increase sales achieved eucan region sales ukraine russia fell short expectations due war supply difficulties also weighed pet poultry business europe overall net sales growth eucan region currency adjusted alamea asia latin america middle east africa region registered sales growth currencyadjusted sales pet segment higher livestock segment sales tcm chinese market region fell currencyadjusted com pared previous year decisive factors decline first zerocovid poli cy china combined numerous lockdowns second difficult market swine segment characterized high feeding husbandry costs well low sales prices income swine producer side result significantly less demand medication prevent diseases swine segment animal health net sales region million eur currency change adjusted usa eucan alamea tcm biopharmaceutical contract manufacturing continued strong biopharmaceutical contract manufacturing business revenue currency growth adjusted higher previous year due strong demand business part biopharmaceutical ners market products order situation entire business developed positively contract resulting high level capacity utilization addition focus product manufacturing process transfers new production facilities vienna salesdiscontinued operations discontinued operations aggregate activities minor strategic importance boehringer ingelheim net sales decreased expected group management report report economic position financial position boehringer ingelheims financial management strategy aims safeguard companys financing means operating cash flow far possible minimize financial risks optimize cost capital cash inflow operating activities million eur despite buildup inventories provide safe care patients revenuerelated buildup receivables due positive business development significantly higher previous year million eur core business also provides basis ability continue investing strategic business development investments totaling million eur could also fully financed operating cash flow million eur financial funds cash flow operating activities cash flow investing activities cash flow financing activities change financial funds cash relevant transactions change financial funds due exchange rate movements valuation adjustments financial funds germany million eur invested biberach ingelheim locations high capital past financial year addition strengthened biopharmaceutical expenditure volume rd location vienna million eur enable business development field animal health boehringer ingelheim investing construction modern plant vaccines highest biological safety standards total investment project million eur approximately million eur paid past financial year cash outflow investing activities taking asset sales account mil lion eur total following disbursements financing activities million eur changes due exchange rate movements measurement adjustments groups financial funds decreased million eur million eur million eur boehringer ingelheim annual report net assets position million eur change change assets intangible tangible assets financial assets fixed assets inventories trade accounts receivable receivables current assets securities cash cash equivalents current assets assets total assets equity liabilities group equity provisions pensions similar obligations tax provisions provisions accounts payable loans thereof residual term year liabilities liabilities difference capital consolidation total equity liabilities december boehringer ingelheims total assets amounted million eur increase million eur compared previous year increase primar ily due higher working capital trade receivables inventories moreover positive curren cy effects million eur increased balance sheet items tangible assets increased million eur result renewed high level investment activity particular strategic expansion business areas bio pharmaceuticals austria germany human pharmaceutical research germany animal health france usa well positive currency effects intangible assets decreased significantly due amortization funds previously held cash invested shortterm investments invested longterm securities financial assets increased result result investments shareholdings group management report report economic position working capital inventories trade receivables increased due buildup stocks ensure security supply higher acquisition production costs due price increases procurement markets currency effects trade accounts receivable also increased result reportingdate revenuerelated circumstances primarily usa germany increase receivables assets due factors increased tax prepay ments positive currency effects assets increased due higher deferred tax assets resulting temporary differences measures consolidated companies tax balance sheets measures consolidated balance sheet pension provisions particular well currency effects equity amounted million eur december decreased slightly million eur result withdrawals also included withdrawals financing boehringer ingelheim foundation well tax payments boehringer ingelheim equity ratio foundation nonprofit foundation promotes excellence basic research natural life sciences according applicable commercial law regulations shareholders tax payments attributable group activities shown profit loss statement tax expenses withdrawals equity ratio fell slightly mainly due increase total assets approximately december addition equity pension provisions longterm liabilities also available group capital long term three items totaled million eur december representing share total assets consequently previous years longterm disposable capital continues cover intangible assets tangible assets well working capital pension provisions increased germany due reduction discount rates due adjustment provisions current development inflation cur rent assumptions pension trends well usa due lower market values plan assets increase provisions correlates change level revenue since includes provisions discounts usa commissions royalty pay ments currency effects also led increase provisions increase liabilities stems exclusively trade payables positive currency effects thirdparty debt duced liabilities declined mainly due release difference arising capital consolidation well deferred income financial position likewise reflects boehringer ingelheims healthy economic development financial year boehringer ingelheim remains soundly financed company making considerable capital expenditure development business research activities resources order ensure longterm growth independence boehringer ingelheim annual report report opportunities risks opportunities risk management assessing risks context holistic opportunities risk management also endeavor take account resulting opportunities opportunity management based strategies objectives company indi vidual businesses operating business units integral part groupwide planning management systems responsible businesses functions bear direct responsibility early systematic identification analysis use opportunities researchdriven biopharmaceutical company boehringer ingelheims current research development activities definition considered opportunity relevant projects already outlined research development chapter also see digital trans formation opportunity see new possibilities use technologies area research development especially clinical development also supporting patients therapy digital transformation also particular importance sales admin istration aim risk management system implemented boehringer ingelheim identify businessspecific risks particular risks jeopardize continued existence company early possible assess reduce reasonable level means suitable measures persons responsible key businesses functions also included process calculating assessing risks groupwide risk information system ensures identified risks carefully analyzed assessed following appropri ate classification adequate risk management measures initiated implementation systematically monitored year review internal audit department performed targeted routine audits well extraordinary audits around world addition adherence legal requirements internal group guidelines main focal points functionality systems ef fectiveness internal controls prevention loss assets efficiency struc tures processes corresponding adjustments optimizations initiated necessary individual risks key risks boehringer ingelheim exposed broken following specific categories financial risks legal risks information technology risks production environmental risks personnel risks industry risks risks identified concrete appear controllable means specific management procedures term abstract used case risks completely controlled even means targeted management procedures regardless probability occurrence group management report report opportunities risks financial risks relevant financial risks turn broken follows currency risks geopolitical risks credit countryspecific risks financial investment shareholding risks currency risks global orientation business activities subject risks opportunities due exchange rate volatility relation us dollar japanese yen also regard emerging markets currencies especially chinese renminbi group monitors quantifies risks regular intervals making predictable future business using relevant hedging strategies appropriate financial instruments forward exchange contracts resultant risks subsequently designated concrete controllable therefore limited geopolitical risks business boehringer ingelheim global company adversely affected geopo litical developments significant risks may arise factors geopolitical tensions changing economic political conditions may impact production sites sales markets global geopolitical developments particular connection rus sian war aggression ukraine constant observation boehringer ingelheim appropriate measures address generally concrete low risks maintain successful global business taken early stage credit countryspecific risks boehringer ingelheim exposed various credit countryspecific risks result international business activities portfolio trade accounts receivable trade ac counts payable identified extraordinary risks group beyond usual level industry also compared previous years applies possible default risks receivables largely hedged economic political risks continue carefully track credit countryspecific risks position respond negative changes timely manner risks consider moderate therefore regarded concrete financial investment shareholding risks group pursues conservative investment strategy management financial assets primary objective longterm preservation real value reflected orien tation portfolio mainly comprises money market bond investments sults concrete controllable limited level risk financial investments net book value strategic investments related companies affected market business circumstances leads higher level volatility fair market value concrete risks covered respective impairments consolidated financial statements boehringer ingelheim annual report legal risks business activities group exposed legal risks distinction made regulatory liability patentprotection risks regulatory risks boehringer ingelheim exposed risks arising legal disputes proceedings well official investigations legal administrative decisions ongoing future proceedings predicted regard resultant risks abstract high addition employees boehringer ingelheim regularly trained compliance regulatory require ments order minimize probability risks occurring liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim currently product liability insurance companys risk profile however absolutely guarantee insurance coverage main tained reasonable cost acceptable conditions sufficient protect boehringer ingelheim claim loss potential claims losses case foreseeable product liability insurance cover partially covers concrete liability risks remaining risk exposure covered provision therefore see moderate risk group furthermore product liability claims could tie substantial financial resources manage ment capacity detrimental companys image event market consid ers medicine unsafe ineffective result unexpected side effects see abstract moderate risk patent protection risks protection innovations trademark patent rights particular importance boehringer ingelheim researchdriven biopharmaceutical company commercial pro tective rights increasingly target attacks breaches taken necessary precautions allow us detect threats early stage commencing appropriate countermeasures defend legal position using legal means available us factors regarded concrete moderate risks information technology risks boehringer ingelheim uses global networked systems core areas operations busi ness production processes well internal external communication also makes use cloudbased thirdparty systems services systems used process store transmit confidential personal data availability integrity confidentiality systems data processed thus highly significant external cyber attacks manipulation systems may result loss information expertise well temporary interruptions business production processes risk considered high concrete view continuously evolving global environment growing frequency cyber attacks risk threats attacks increased last years since people increas ingly working home employees thus access sensitive data within less secure environments group management report report opportunities risks boehringer ingelheim countering risk means continuous process analysis improvements well preventive reactive measures helps identify ward current threats minimize potential damage production environmental risks quality management system compliance processes continuously optimized close cooperation relevant authorities order ensure compliance cgmp standards current good manufacturing practices risks area continue high significance group classified abstract boehringer ingelheim implemented riskmitigating measures past year order counter covidspecific threats production activ ities included physical segregation production teams possible obligation wear mask increase supply disinfectants inhouse initiatives testing covid status employees order guarantee supply products market implemented measures guarantee reliable highquality supplies customers addition supplier man agement procurement side also involves building internal standby capacities overall represents concrete moderate risk risks areas environment health safety sustainability ehss preemp tively minimized ensuring global adherence high safety standards appropriate emer gency plans drawn possible incidents kind practiced sub jected comprehensive quality testing regular intervals result measures risks classed concrete limited personnel risks companies boehringer ingelheim exposed demographic change sultant risk affected lack appropriately qualified personnel potential risk substantial impact companys business activities therefore cluded longterm planning process many years gained strategic significance result boehringer ingelheim counters risk means comprehensive personnel concept also presents group opportunities context global personnel management regardless ethnic background gender religion offer companys employ ees development opportunities based professional abilities social skills personal ap titudes willingness take responsibility accordance needs company view measures described risk regarded concrete moderate boehringer ingelheim also exposed human resources risks result covid pandemic pathogen spread would significant impact outside production activities company therefore closely monitoring situation vicinity sites also emphasizes working home extent necessary using digital applications rather inperson meetings view measures consid ered concrete moderate risk boehringer ingelheim annual report industryspecific risks boehringer ingelheim exposed business risks specific pharmaceutical indus try risks materialized part past financial year becoming increas ingly important boehringer ingelheim due effects continue classed abstract high addition loss exclusivity products established market risks associated development registration new medicines industry specific risks increasingly include changing restrictive requirements relating pricing reimbursement many sales markets frequently prices pharmaceutical products subject state monitoring regulation also price pressure state imbursement systems due cheaper generic drugs boehringer ingelheim keeping close eye various changes respective sales markets takes appropriate measures response current developments net book value individual balance sheet items exposed changes market business conditions therefore also changes fair values event necessary im pairments may significant noncash impacts earnings balance sheet ratios applies particular intangible assets including goodwill essentially stem past company acquisitions relevant risks assessed taken account part preparation consolidated financial statements overall statement risk situation current perspective aware risks alone conjunction risks could lead lasting impairment companys net assets financial earnings posi tion could jeopardize continued existence boehringer ingelheim group management report report expected developments report expected developments boehringer ingelheim look back successful financial year achieved objectives terms contribution wellbeing patients livestock pets well terms key financial data even exceeded terms expected growth despite volatile environment able ensure companys sustainable development profitable growth influential developments also influence coming financial year also present challenges us expect general inflation remain level recent years despite countermeasures taken central banks high energy prices resulting war ukraine ease medium term particularly europe also impact chinas move away zerocovid policy initiated end yet fully assessed continue expect china limited global presence well subdued national development continue look confidence plan improve lives patients imals innovation thereby also achieving sustainable growth however outlook coming financial year remains difficult current economic situation greatest uncertainty coming years potential impact various govern ment economic recovery sustainability support programs respective governments budget planning whether result policy shifts related innovative medicines expect moderate market growth prescription pharmaceuticals excluding covid medication also observing increasing global institutional efforts lower prices medicinal products view development financial ability act regard sus tainable growth innovation remains great importance us expect moderate market growth new financial year animal health sector research innovation particularly important together business part ners intend continue provide customers innovative solutions boehringer ingelheim various new launches pet livestock segments enable growth magnitude market priorities biopharmaceuticals business area supplying market products contract manufacturing business partners utilization largescale cell culture facility vienna continue focus expect boehringer ingelheim achieve slight yearonyear increase net sales comparable basis adjusted currency extraordinary effects consistently high rd expenditure increased line strategic focus continuing drive growth flow new products achieved goal obtaining rd external innovation partner ships continue actively pursue strategy invest exter nal rd close investigation therapeutic benefit associated prospects success flow innovative medicines research development pipeline shows short medium longterm growth potential expect see increase rd investments new medicines intend reach new milestones research de velopment well individual market approvals boehringer ingelheim annual report addition patent expiry major challenges facing researchdriven pharmaceutical industry increasing amount investment rd well bigger hurdles increased costs associated product approvals also particular note previously mentioned growing cost pressure healthcare systems last two years pandemic searchdriven pharmaceutical companies displayed unprecedented level networking energy develop solutions interests patients extremely quickly thereby proving societal value research innovation nevertheless sustainable steps required involving politicians supporting stakeholder groups pharmaceutical companies contribution value overall economic added value increasing efficiency healthcare system whole continues appropriately rewarded animal health research likewise requires major investments preventive research diagnostic options conjunction long planning development cycles new products growing public cost pressure means business less predictable requires us quickly recognize seize opportunities human pharma animal health continuously monitoring adjusting costs strategies implemented measures business areas accelerate speed response changes reduce complexity organization optimize cost base way creating potential capital expenditure securing companys longterm success expect boehringer ingelheim achieve slight improvement operating income despite increased level investment research development comparable basis adjusted currency extraordinary effects boehringer ingelheim develops therapies fundamentally change lives today gen erations come traditional family enterprise thereby ensure competitiveness longterm entrepreneurial independence confident achieve ambitious targets business areas thanks great innovative strength rests comprehensive portfolio prospective products global presence support highly qualified motivated employeesconsolidated financial statements verview selected consolidated companies consolidated balance sheet consolidated profit loss statement consolidated cash flow statement statement changes group equity n otes consolidated financial statements independent auditors report boehringer ingelheim annual report overview selected consolidated companies ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aires italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium p r mexico p usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein boehringer ingelheim veterinary boehringer ingelheim medicine belgium nv evergem netherlands r biopharmaceuticals gmbh ingelheim rhein boehringer ingelheim animal health brazil p netherlands bv alkmaar boehringer ingelheim middle east africa gmbh boehringer ingelheim animal health ingelheim rhein brasil ltda paulo new zealand boehringer ingelheim boehringer ingelheim animal health therapeutics gmbh canada new zealand limited auckland ochsenhausen boehringer ingelheim animal health bi x gmbh canada inc burlington philippines ingelheim rhein boehringer ingelheim animal health china p r philippines inc makati city nanchang boehringer ingelheim animal health co ltd nanchang puerto rico p boehringer ingelheim animal boehringer ingelheim animal health health shanghai co ltd puerto rico llc barceloneta shanghai boehringer ingelheim animal south africa health operations china co ltd taizhou boehringer ingelheim animal health boehringer ingelheim vetmedica south africa pty ltd midrand china co ltd taizhou gauteng denmark p south korea boehringer ingelheim animal health boehringer ingelheim animal health denmark copenhagen korea ltd seoul france p r spain boehringer ingelheim animal health boehringer ingelheim animal health france lyon espaa sa barcelona great britain p boehringer ingelheim animal health uk limited bracknell distribution p production r research development consolidated financial statements overview selected consolidated companies ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina czech republic japan p r south africa boehringer ingelheim sa boehringer ingelheim spol sro nippon boehringer ingelheim co ingelheim pharmaceuticals buenos aires prague ltd tokyo proprietary ltd midrand gauteng boehringer ingelheim seiyaku australia denmark yamagata south korea boehringer ingelheim pty ltd boehringer ingelheim danmark boehringer ingelheim korea ltd north ryde copenhagen mexico p seoul boehringer ingelheim mexico sa de austria p r ecuador cv mexico city spain p boehringer ingelheim vetmedica sa boehringer ingelheim rcv boehringer ingelheim del ecuador boehringer ingelheim espaa sa de cv guadalajara gmbh co kg vienna cia ltda quito barcelona boehringer ingelheim promeco sa boehringer ingelheim pharma de cv mexico city gesellschaft mbh vienna finland sweden f po ar ts hc oh lou gn ig es gin es st eit lu lst c f h ar fm mol hku l va ir ee n na b eso pe oh oringer ingelheim finland ky netherlands b sto oe ch kr hin og lmer ingelheim aktiebolag viratherapeutics gmbh rum boehringer ingelheim bv alkmaar france switzerland r belgium new zealand boehringer ingelheim france sas boehringer ingelheim schweiz boehringer ingelheim scomm paris boehringer ingelheim nz ltd gmbh basel brussels auckland nbetherapeutics ag basel great britain amal therapeutics sa geneva brazil p norway boehringer ingelheim ltd boehringer ingelheim brasl bracknell boehringer ingelheim norway ks taiwan qumica e farmaceutica ltda asker paulo boehringer ingelheim taiwan ltd greece p taipei peru canada boehringer ingelheim hellas single member sa athens boehringer ingelheim peru sac thailand boehringer ingelheim canada ltd lima toronto boehringer ingelheim thai ltd hong kong bangkok philippines chile boehringer ingelheim hong kong ltd hong kong boehringer ingelheim philippines trkiye boehringer ingelheim ltda inc makati city santiago de chile boehringer ingelheim ila ticaret india istanbul poland china p boehringer ingelheim india private ltd mumbai boehringer ingelheim sp z oo usa p r boehringer ingelheim shanghai warsaw pharmaceuticals co ltd shanghai boehringer ingelheim indonesia p pharmaceuticals inc boehringer ingelheim pt boehringer ingelheim indonesia portugal wilmington delaware biopharmaceuticals china ltd jakarta boehringer ingelheim portugal lda boehringer ingelheim fremont inc shanghai lisbon wilmington delaware boehringer ingelheim china israel boehringer ingelheim usa investment co ltd shanghai russia corporation wilmington delaware bi x ehealth technology shanghai boehringer ingelheim israel ltd co ltd shanghai tel aviv ooo boehringer ingelheim moscow vietnam colombia italy p saudi arabia boehringer ingelheim animal health vietnam limited liability company boehringer ingelheim sa boehringer ingelheim italia spa boehringer ingelheim saudi arabia ho chi minh city santa f de bogot milan trading riyadh boehringer ingelheim vietnam ltd bidachem spa fornovo giovanni ho chi minh city croatia serbia boehringer ingelheim zagreb doo boehringer ingelheim serbia doo zagreb beograd belgrade boehringer ingelheim annual report consolidated balance sheet assets million eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets prepaid expenses deferred tax assets exceeding amount plan assets total assets equity liabilities million eur notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred income deferred tax liabillities total equity liabilities explanations see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement consolidated profit loss statement million eur notes net sales changes finished goods work process work capitalized operating income total revenues cost materials personnel expenses amortization intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net income noncontrolling interests group profit explanations see relevant section notes consolidated financial statements due legal requirements shareholders personal taxes arising group business activities shown withdrawals group reserves boehringer ingelheim annual report consolidated cash flow statement million eur income taxes including noncontrolling interests amortization depreciation writedowns reversal writedowns intangible tangible financial assets change provisions pensions similar obligations including change plan assets change provisions noncash income expenses gain disposals consolidated companies gains losses disposals fixed assets grants received change inventories change accounts receivable assets related investing financing activities change accounts payable liabilities related investing financing activities interest income interest expenses income investments income expenses income taxes income taxes paid cash flow operating activities payments acquire intangible fixed assets payments acquire tangible fixed assets payments acquire financial fixed assets payments acquire plan assets proceeds disposals intangible fixed assets proceeds disposals tangible fixed assets proceeds disposals financial fixed assets proceeds disposals consolidated entities interest received income dividends cash flow investing activities cash receipts grants interest paid proceeds capital contributions minority shareholders cash payments shareholders parent company proceeds loans cash repayments loans cash flow financing activities consolidated financial statements consolidated cash flow statement statement changes group equity consolidated cash flow statement continued million eur change financial funds cash relevant transactions change financial funds due exchange rate movements valuation adjustments financial funds financial funds line also contains shareholders personal taxes arising group business activities according legal requirements included groups tax expenses cash cash equivalents securities within current assets source funds use funds statement changes group equity balance sheet equity currency attributable non shareholders group conversion parent controlling million eur capital reserves difference company interests group equity balance withdrawals net income reduction recognition deferred tax liabilities recognized directly equity changes consolidated companies currency effects balance withdrawals net income changes consolidated companies currency effects balance shareholders capital consists equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising group business activities shown withdrawals group reserves boehringer ingelheim annual report notes consolidated f inancial statements principles methods general principles consolidated financial statements ch boehringer sohn ag co kg financial year prepared accordance section german commercial code handelsgesetzbuch hgb line legal requirements prepare consolidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements consolidated cash flow statement statement changes group equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements subtotals added con solidated profit loss statement furthermore individual items consolidated balance sheet consolidat ed profit loss statement combined items presented explained separately notes consolidated financial statements additional disclosures required individual items also found notes consolidated financial statements registry information parent company registered name ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company holds participation subsidiary boehringer ingelheim group boehringer ingelheim group consists total affiliated companies germany abroad subsidiaries included consolidated financial statements ch boehringer sohn ag co kg full consolida tion rules ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bears majority risks rewards economic terms ch boehringer sohn ag co kg holds majority voting rights subsidiaries either directly indirectly accordance section hgb subsidiaries included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total consolidated financial statements notes consolidated financial statements amount sales equity net income year subsidiaries included consolidation accounts less one percent aggregated group financial statements totals three subsidiaries ongo ing restrictions control due terms articles association accordance section hgb companies consolidated either total number affiliated companies decreased four compared previous year three companies founded three companies lost separate legal identities merger three affiliated companies liquidated one affiliated company sold following subsidiaries exempted reporting disclosure obligations pursuant section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim finanzierungs gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim rd beteiligungs gmbh ingelheim rhein boehringer ingelheim animal health france participations gmbh ingelheim rhein boehringer ingelheim finanzinvest gmbh ingelheim rhein due boehringer ingelheim gmbh making use exemption reporting disclosure obligations pursu ant section hgb disclosures required accordance section f hgb provided shareholders meeting boehringer ingelheim gmbh resolved accordance section german act limit ed liability companies gesetz betreffend die gesellschaften mit beschrnkter haftung gmbhg set proportion women management target achieved end financial year accordance section gmbhg managing directors boehringer ingelheim gmbh decided set proportion women first management level managing directors well second management level managing directors targets achieved end financial year following subsidiaries exempted reporting disclosure obligations pursuant section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim participates one joint venture included consolidated financial state ments using either proportionate method equity method since material furthermore boehringer ingelheim holds interest associated companies recognized using equity method either due lack significance using equity method balance sheet total consolidated profit loss affected less one percent boehringer ingelheim annual report consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiaries consolidation first time accordance section hgb companies included consolidation first time respective date company became subsidiary book value shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining positive bal ance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realization principle section conjunction section half sentence hgb historical cost principle section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euros using modified closing rate method accordance section hgb using modified closing rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using annual average rate resulting translation differences reported within consoli dated equity reserves balance sheet currency conversion difference exchange rates groups important currencies changed follows reporting year basis eur spot rate average rate us dollar japanese yen chinese renminbi consolidated financial statements notes consolidated financial statements accounting policies fixed assets acquired intangible assets property plant equipment carried cost less scheduled straightline amortiza tion depreciation determined consideration technical economic circumstances based following useful lives goodwill years intangible assets years buildings years technical facilities machines years facilities operating equipment years straightline depreciation amortization used consolidated financial statements additional write downs recorded reflect impairments value assets considered permanently impaired manufacturing costs include materials labor manufacturing costs appropriate portion material labor overheads depreciation fixed assets extent caused production manufacturing costs include financing costs capitalized intangible assets finite useful lives financial assets primarily include investment securities shareholder rights loans carried lower cost fair market value impaired event reasons impairment losses recognized previous fi nancial years longer applicable corresponding reversals recorded current assets prepaid expenses deferred income exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalized lower average acquisition prices fair market value balance sheet date finished goods work progress measured manufacturing cost basis individual calculations taking account directly attributable costs materials direct labor costs special direct costs appropriate share material production overhead costs productionrelated depreciation goods resale measured lower either acquisition cost fair market value boehringer ingelheim annual report identifiable risks inventories arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments measurement carried lossfree deductions made expected sales prices reflect costs yet incurred receivables assets recognized cost less allowances specific risks general credit risk low interest noninterestbearing receivables term one year discounted securities classified current assets solely include securities recognized lower cost applicable value resulting stock exchange market prices reporting date cash cash equivalents consisting cash balances banks checks recognized lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred income recorded accordance section hgb includes proceeds represent income respect defined period time balance sheet date fair market value pension plan assets corresponding present value pension obligations set according german gaap exceeding amount plan assets capitalized separately group reserves group reserves include retained earnings consolidated subsidiaries prior current years consoli dation entries affect earnings difference capital consolidation difference capital consolidation reported december result business swap boehringer ingelheims consumer healthcare business sanofis animal health business completed january resulted difference capital consolidation million eur difference amortized estimated period years remaining balance difference amounted million eur de cember difference capital consolidation primarily influenced current year release million eur income release difference arising capital consolidation included operating income release made corresponding amortization assets acquired company identified purchase price allocation previously recognized companys balance sheet consolidated financial statements notes consolidated financial statements provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judgment including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions interest rate results average market interest rate last ten years case provisions average market inter est rate last seven years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions since environmental protection measures cases expected result permanent burden relevant pro visions calculated basis perpetual annuity taking consideration cost price increases well interest effects current costs adjusted inflation basis average rate change producer price index industrial products since introduction euro ultimate forward rate ufr provided european insurance occupational pensions authority eiopa used discounting accounts payable loans accounts payable loans recognized settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred income commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using companyspecific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used next five years deferred tax assets liabilities reported without offsetting boehringer ingelheim annual report notes consolidated balance sheet intangible assets acquired concessions advance million eur similar rights goodwill payments total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortization balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes consolidated financial statements tangible assets advance technical facilities payments land facilities operating construction million eur buildings machines equipment progress total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value boehringer ingelheim annual report financial assets investments investments loans affiliated related related investment million eur companies companies companies securities loans total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders consolidated financial statements notes consolidated financial statements inventories million eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual term residual term million eur year year trade accounts receivable receivables affiliated companies receivables related companies assets receivables affiliated companies almost exclusively consist receivables loans receivables related companies primarily consist trade accounts receivable assets include receivables shareholders million eur previous year million eur provisions million eur pension provisions similar obligations tax provisions provisions boehringer ingelheim annual report provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data germany example g mortality tables published prof dr klaus heubeck adjusted groupspecific death probabilities invalidity rates pension obligations signifi cant countries calculated basis following actuarial parameters december germany usa discount rate salary increase pension increase discount rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts million eur previous year mil lion eur assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date million eur related amount pension obligations similar obligations million eur tax provisions tax provisions also include provisions double taxation risks resulted following implementation action plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps consolidated financial statements notes consolidated financial statements provisions provisions mainly include provisions discounts guarantees personnelrelated provisions provisions outstanding invoices provisions litigation legal claims compensation damages accounts payable loans residual term residual term less thereof less million eur year year years year bank loans accounts payable thereof trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities thereof taxes million eur social security liabilities million eur previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders amounted million eur previous year million eur presented within liabilities accounts payable affiliated companies include loans amounting million eur previous year million eur trade accounts payable amounting million eur previous year million eur boehringer ingelheim annual report notes consolidated profit loss tatement structure consolidated profit loss statement based total cost format taxes included operating expenses net sales business million eur human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations region million eur americas europe asia australia africa aaa operating income operating income includes foreign currency gains million eur previous year million eur cost materials million eur costs raw material supplies goods resale expenditure services consolidated financial statements notes consolidated financial statements personnel expenses million eur wages salaries social benefits retirement benefits thereof retirement benefits interest effects measurement provisions pensions similar obligations shown financial income average headcount production marketing sales research development administration apprentices amortization intangible assets depreciation tangible assets amortization intangible assets depreciation tangible assets include impairment losses million eur previous year million eur operating expenses operating expenses include foreign currency losses million eur previous year million eur furthermore operating expenses include expenses research development medical studies marketing freight expenses third party repairs services cost legal risks restructurings administrative expens es well contributions fees taxes boehringer ingelheim annual report financial income million eur interest expenses similar expenses amortization loss disposal financial fixed assets shortterm investments income investment securities longterm loans interest income similar income interest expenses similar expenses item includes interest result provisions pensions similar obligations provisions amount million eur previous year million eur well interest expenses similar expenses amount million eur previous year million eur gains losses plan assets interest expense relating pension similar obligations offset accordance section sentence hgb total million eur interest expense plan assets million eur interest expense relating pension similar obligations included interest expenses similar expenses holding income million eur writedowns financial assets writeups financial assets income related companies thereof disposal related companies income taxes million eur current income taxes deferred taxes current income taxes primarily include corporation trade tax expenses consolidated companies consolidated financial statements notes consolidated financial statements total balance deferred tax assets balance sheet date amounted million eur previous year million eur deferred tax assets primarily arise difference carrying amounts provisions pension obligations discounts taxable goodwill intangible assets inventories tangible assets deferred tax liabilities million eur previous year million eur recorded primarily relate differences carrying amounts intangible assets tangible assets inventories provisions net income net income positively influenced nonperiod income primarily reversal provisions amount million eur previous year million eur negatively influenced nonperiod expens es particular additional expenses related provisions amount million eur previous year million eur notes consolidated cash flow statement consolidated cash flow statement shows changes financial funds boehringer ingelheim group resulting cash inflows outflows reporting year financial funds contain cash cash equivalents well secu rities converted cash shortterm changes balance sheet items affiliated companies included translated using average rates year balance sheet financial funds carried spot rate effect exchange rate changes financial funds shown separately financial funds december comprised following items million eur cash cash equivalents securities classified current assets financial funds included million eur restricted funds balance sheet date boehringer ingelheim annual report disclosures contingent liabilities million eur liabilities guarantees warranties granting securities thirdparty liabilities contingent liabilities assumed careful risk assessment connection business activities affiliated companies risk call contingent liabilities assessed low based information available balance sheet date risks probability availment reasonable balance sheet date recorded provision financial commitments offbalance sheet transactions million eur rental lease obligations residual financial commitments within rental lease obligations million eur previous year million eur relate longterm rental agreements subsidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilize properties fully indications time residual financial commitments include investments future effects cash flows million eur previous year million eur derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging delivery goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organizational processes set internal guidelines strict separation trading processing documentation control consolidated financial statements notes consolidated financial statements risk positions regularly tracked analyzed measured special groupwide financial report positions entered periodically reevaluated monitored fair value derivative financial instruments calculated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions million eur recognized currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognized balance sheet date derivative financial instruments included hedge accounting valuation units follows nominal value fair value million eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecast transactions accordance section hgb met foreign currency forward exchange contracts recognized balance sheet line net hedge presentation method following accounting policies apply recognition valuation units accordance section hgb economic hedges accounted financial statements use valuation units valuation units recognized foreign currency based net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable opposing changes value hedged item hedging instrument fully offset critical terms aturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation units boehringer ingelheim annual report december hedges highly probable forecasted net cash flows recognized follows january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december usd january may jpy net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy january february net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd consolidated financial statements notes consolidated financial statements furthermore december valuation units foreign currency receivables recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value rub rub rub december valuation units foreign currency receivables resulting loans recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value cad cad cad chf chf chf cny cny cny mxn mxn mxn thb thb thb twd twd twd usd usd usd amount hedged foreign currency risk correlates relative change exchange rate plan ning date realization date forecasted transactions currencies appreciate depreciate euro would foreign currency risk million eur without hedging research development expenses million eur research development expenses noncapitalized research development expenses include among items costs associated clinical studies boehringer ingelheim annual report total auditor fees total fees charged group auditor financial year amounted million eur million eur relates audits financial statements million eur assurance services million eur tax adviso ry services million eur services subsequent events since end financial year become aware events material significance group could lead reappraisal net assets financial earnings position shareholdings list companies included consolidated financial statements list shareholdings presented ac cordance section hgb included audited consolidated financial statements submitted german federal gazette ingelheim rhein february boehringer ag board managing directors hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer consolidated financial statements independent auditors report independent auditors report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statements audit opinion group management report audited consolidated financial statements ch boehringer sohn ag co kg ingelheim rhein subsidiaries group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement changes group equity financial year january december notes consolidated financial statements including recognition measurement policies presented therein addition audited group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consolidated financial statements audit opinion group management report accompanying consolidated financial statements comply material respects requirements german commercial law give true fair view assets liabilities financial position group december financial performance financial year january december compliance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified opinion consolidated financial statements audit opinion group manage ment report contrary section number letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recognized former members board managing directors disclosed notes consolidated financial statements conducted audit consolidated financial statements group management report accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report inde pendent group entities accordance requirements german commercial professional law fulfilled german professional responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinions consolidated financial statements group management report boehringer ingelheim annual report information management responsible information information comprises annual report exception audited consolidated financial statements group management report auditor 's report opinions consolidated financial statements group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report audited content knowledge obtained audit otherwise appears materially misstated responsibilities management consolidated financial statements group management report management responsible preparation consolidated financial statements comply material respects requirements german commercial law consolidated financial statements compli ance german legally required accounting principles give true fair view assets liabilities financial position financial performance group addition management responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud ie fraudulent financial reporting misappropriation assets error preparing consolidated financial statements management responsible assessing groups ability continue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore management responsible preparation group management report whole provides appropriate view groups position material respects consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development addition management responsible arrangements measures systems considered necessary enable preparation group management report accordance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report consolidated financial statements independent auditors report auditors responsibilities audit consolidated financial statements group management report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent consolidated financial statements knowledge obtained audit complies german legal requirements appro priately presents opportunities risks future development well issue auditors report includes opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements group management report exercise professional judgment maintain professional skepticism throughout audit also identify assess risks material misstatement consolidated financial statements group management report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinions risk detecting material misstatement resulting fraud higher risk detecting material misstate ment resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal controls obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing opinion effec tiveness systems evaluate appropriateness accounting policies used management reasonableness estimates made management related disclosures conclude appropriateness managements use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated finan cial statements group management report disclosures inadequate modify respective opinions conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease able continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles boehringer ingelheim annual report obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express audit opinions consolidated financial statements group management report responsible direction supervision performance group audit remain solely responsible audit opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides perform audit procedures prospective information presented management group management report basis sufficient appropriate audit evidence evaluate particular significant assumptions used management basis prospective information evaluate proper derivation prospective information assumptions express separate opinion prospective information assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main february kpmg ag wirtschaftsprfungsgesellschaft original german version signed signed kneisel signed bernau wirtschaftsprfer wirtschaftsprferin german public auditor german public auditor consolidated financial statements independent auditors report boehringer ingelheim annual report comparison balance sheet financial data assets december million eur intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes exceeding amount plan assets financial funds current assets total assets equity liabilities december million eur shareholders capital group reserves incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred income total liabilities incl deferred taxes deferred income total equity liabilities summary selected financial data million eur net sales operating income operating income net sales income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets depreciation tangible assets imprint assets december ch boehringer sohn ag co kg million eur binger strasse intangible assets ingelheim rhein tangible assets germany financial assets telephone fax fixed assets inventories contact accounts receivable assets incl prepaid expenses corporate affairs deferred taxes exceeding amount plan assets matthias reinig financial funds pressboehringeringelheimcom current assets boehringeringelheimcom total assets issued equity liabilities december ch boehringer sohn ag co kg represented board managing directors million eur hubertus von baumbach chair shareholders capital carinne brouillon dr michel pairet group reserves incl balance sheet currency conversion difference jean scheftsik de szolnok michael schmelmer group profit concept design layout equity attributable parent company st kommunikation gmbh mainz noncontrolling interests wwwstde group equity difference capital consolidation photos provisions incl deferred taxes andreas reeg seite urban zintel seite liabilities incl deferred income total liabilities incl deferred taxes deferred income copyright total equity liabilities ch boehringer sohn ag co kg rights reserved part annual report may summary selected financial data reproduced transmitted form means electronic photocopy without permission writing ch boehringer million eur sohn ag co kg figures third parties used annual net sales report based data available time financial state ments drawn operating income operating income net sales income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets depreciation tangible assets